Using Risk Models for Breast Cancer Prevention Air date: Wednesday, February 27, 2013, 3:00:00 PM Description: Wednesday Afternoon Lecture Series Dr. Gail uses statistical methods for the design and analysis of epidemiologic studies including studies of genetic factors and models to predict the absolute risk of disease. Epidemiologic studies have established several risk factors for breast cancer such as family history, age when giving birth for the first time, biopsy findings, and mammographic density. These factors can be combined with breast cancer incidence rates to construct models of absolute risk of breast cancer. Absolute risk is the risk of developing a disease over a defined age interval or time period; relative risk is used to compare risks in different groups of people. Absolute risk is useful for counseling women and in public-health applications. In counseling, absolute risk estimates provide realistic perspectives and inform decision-making such as when or whether to begin having screening mammographies. Absolute risk estimates are also useful in weighing the risks and benefits, for example, of chemopreventive therapies such as tamoxifen or raloxifene. Public health applications of risk models include designing chemoprevention trials; implementing "high risk" prevention strategies that focus only on women who are at highest risk for breast cancer; assessing the potential of preventive interventions to reduce absolute breast cancer risk in the population; and using risk estimates to allocate prevention resources under cost constraints. Dr. Gail will review the usefulness of risk models in these applications and the potential of additional risk factors, such as single nucleotide polymorphisms, to improve the performance of those models. Author: Mitchell H. Gail, M.D., Ph.D., National Cancer Institute Runtime: 01:03:57 Permanent link: http://videocast.nih.gov/launch.asp?17823
Просмотров: 1523 nihvcast
BSI-201 is described as a prodrug of 4-iodo-3-nitrosobenzamide, an agent that covalently inhibits PARP1 by binding to its first zinc finger under cell-free conditions. Treatment of 120 μM BSI-201 plus buthionine sulfoximine (BSO) induces a 95% cell death among 855-2 cells(http://www.selleckchem.com/products/BSI-201.html)
Просмотров: 219 PARP Inhibitors
TRACO 2018 - Breast cancer and Epidemiology Air date: Monday, October 22, 2018, 4:00:00 PM Category: TRACO Runtime: 02:03:13 Description: Breast cancer and Epidemiology For more information go to http://ccr.cancer.gov/training/trainee-resources/courses-workshops/traco Author: Farah Zia, MD, NCI, NIH and Neil Caporaso, MD, NCI, NIH Permanent link: https://videocast.nih.gov/launch.asp?26138
Просмотров: 80 nihvcast
Ashwagandha is a key ingredient in many supplements and shakes. What is it supposed to do, and does it work? REFERENCES: Andrade C, Aswath A, Chaturvedi SK, Srinivasa M, Raguram R.A double-blind, placebo-controlled evaluation of the anxiolytic efficacy ff an ethanolic extract of withania somnifera. Indian J Psychiatry. 2000 Jul;42(3):295-301. Ashwagandha. NIH. Medline Plus. https://medlineplus.gov/druginfo/natural/953.html#Safety. Accessed August 04, 2018. Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther. 2013 Jul;12(4):312-22. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012 Jul;34(3):255-62. Chengappa KN, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R.Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder. J Clin Psychiatry. 2013 Nov;74(11):1076-83. Durg S, Dhadde SB, Vandal R, Shivakumar BS, Charan CS. Withania somnifera (Ashwagandha) in neurobehavioural disorders induced by brain oxidative stress in rodents: a systematic review and meta-analysis. J Pharm Pharmacol. 2015 Jul;67(7):879-99. Halder B, Singh S, Thakur SS. Withania somnifera Root Extract Has Potent Cytotoxic Effect against Human Malignant Melanoma Cells. PLoS One. 2015 Sep 3;10(9). Kakar SS, Ratajczak MZ, Powell KS, Moghadamfalahi M, Miller DM, Batra SK, Singh SK. Withaferin A alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells. PLoS One. 2014 Sep 29;9(9):e107596. Kalani A, Bahtiyar G, Sacerdote A. Ashwagandha root in the treatment of non-classical adrenal hyperplasia. BMJ Case Rep. 2012 Sep 17;2012. Kaur T, Singh H, Mishra R, Manchanda S, Gupta M, Saini V, Sharma A, Kaur G.Withania somnifera as a potential anxiolytic and immunomodulatory agent in acute sleep deprived female Wistar rats. Mol Cell Biochem. 2017 Mar;427(1-2):91-101. Kim G, Kim TH, Kang MJ, Choi JA, Pack DY, Lee IR, Kim MG, Han SS, Kim BY, Oh SM, Lee KB, Kim DJ, Park JH. Inhibitory effect of withaferin A on Helicobacter pylori‑induced IL‑8 production and NF‑κB activation in gastric epithelial cells. Mol Med Rep. 2016 Jan;13(1):967-72. Konar A, Shah N, Singh R, Saxena N, Kaul SC, Wadhwa R, Thakur MK. Protective role of Ashwagandha leaf extract and its component withanone on scopolamine-induced changes in the brain and brain-derived cells. PLoS One. 2011;6(11):e27265. Kurapati KR, Atluri VS, Samikkannu T, Nair MP. Ashwagandha (Withania somnifera) reverses β-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND). PLoS One. 2013 Oct 16;8(10). Manchanda S, Mishra R, Singh R, Kaur T, Kaur G.Aqueous Leaf Extract of Withania somnifera as a Potential Neuroprotective Agent in Sleep-deprived Rats: a Mechanistic Study. Mol Neurobiol. 2017 May;54(4):3050-3061. Mondal S, Mandal C, Sangwan R, Chandra S, Mandal C. Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol Cancer. 2010 Sep 13;9:239. Panda S, Kar A. Changes in thyroid hormone concentrations after administration of ashwagandha root extract to adult male mice. J Pharm Pharmacol. 1998 Sep;50(9):1065-8. Sehgal VN, Verma P, Bhattacharya SN.Fixed-drug eruption caused by ashwagandha (Withania somnifera): a widely used Ayurvedic drug. Skinmed. 2012 Jan-Feb;10(1):48-9. Shah N, Singh R, Sarangi U, Saxena N, Chaudhary A, Kaur G, Kaul SC, Wadhwa R. Combinations of Ashwagandha leaf extracts protect brain-derived cells against oxidative stress and induce differentiation. PLoS One. 2015 Mar 19;10(3). van der Hooft CS, Hoekstra A, Winter A, de Smet PA, Stricker BH. Thyrotoxicosis following the use of ashwagandha. Ned Tijdschr Geneeskd. 2005 Nov 19;149(47):2637-8. Wadhwa R, Singh R, Gao R, Shah N, Widodo N, Nakamoto T, Ishida Y, Terao K, Kaul SC. Water extract of Ashwagandha leaves has anticancer activity: identification of an active component and its mechanism of action. PLoS One. 2013 Oct 10;8(10). Wankhede S, Langade D, Joshi K, Sinha SR, Bhattacharyya S. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. J Int Soc Sports Nutr. 2015 Nov 25;12:43.
Просмотров: 2111 Wellness with Dr. Meghan MD
Learn about the latest in research for advanced breast cancer with two researchers from NCI's Center for Cancer Research, Dr. Stan Lipkowitz, Chief of the Women's Malignancies Branch, and Dr. Alexandra Zimmer, Staff Clinician in the Women's Malignancies Branch. http://www.cancer.gov/socialmediaevents
Просмотров: 591 National Cancer Institute
hi, this is a Bloomberg West innovators segment aired on the 20 dec 2011. It reports on the ongoing phase II trial of antigen express's ae37 cancer vaccine, after strong results posted at the Sabcs 2011 a week ago...... antigen express in owned by Generex biotechnology better days :)
Просмотров: 3177 jon al
TRACO 2017 - Ovarian Cancer in the Genomics Era and Immune checkpoints Air date: Monday, September 25, 2017, 4:00:00 PM Category: TRACO Runtime: 01:50:04 Description: Translational Research in Clinical Oncology (TRACO) Recent advances in understanding cancer biology are beginning to be translated into improvements in diagnosis and treatment of cancer. In the post-genome era, we increasingly rely on strong collaboration between basic and clinical scientists to develop novel approaches for treatment of human disease. The NCI Center for Cancer Research (CCR) is one of the largest cancer research organizations in the world, with more than 200 principal investigators, and has played a major role in developing and implementing many new technologies, such as nanotechnology, next generation sequencing, genomics and proteomics. For more information go to http://ccr.cancer.gov/trainee-resources-courses-workshops-traco Author: Christina M. Annunziata, MD, PhD, NCI, NIH and Stephanie L. Goff, M.D., NCI, NIH Permanent link: https://videocast.nih.gov/launch.asp?23483
Просмотров: 1272 nihvcast
A GREAT YOU-TUBER IS THE BEST SCIENTIST ON EARTH - 1 of 3056 Medical Cannabis Research Trails/Studies/Facts from Government website http://www.ncbi.nlm.nih.gov/pubmed/?term=medical+cannabis http://phoenixtears.ca/dosage-information/ Rick Simpson Oil Dosages RSO BHO ISO https://www.facebook.com/pages/Rick-Simpson http://www.projectcbd.org/medicine/dosage/ 10,000+ strains with CBD % - lab test results + photos http://live.canna-test.com/Explore.aspx The surprising story of medical marijuana and pediatric epilepsy: Josh Stanley at TEDxBoulder http://www.youtube.com/watch?v=ciQ4ErmhO7g 1947 - CANNABIS EPILEPSY STUDY http://antiquecannabisbook.com/chap03/Epilepsy/Epilepsy-P1.htm All too often, physicians refrain from recommending cannabis use by patients because they learned nothing about cannabis and the endocannabinoid system in medical school and cannot knowledgeably advise patients about dosage, safety, side effects, mechanism of action, etc. Cannabidiol and THC act synergistically to potentiate their respective therapeutic attributes. Thus, a CBD-dominant strain or product, while appropriate in some cases, is not necessarily a superior treatment option compared to a balanced CBD-rich remedy with an equal amount of CBD and THC. Different ratios of CBD and THC are more suitable for different conditions and different individuals. CBD is a non-psychoactive compound that can lessen or neutralize the psychoactivity of THC, which some people find unpleasant and difficult to tolerate. A patent's sensitivity to THC is a key factor in determining appropriate dosages and ratios for a CBD-rich treatment regimen. http://www.canorml.org/ http://norml.ca/ http://www.safeaccessnow.org/ http://medicalmarijuana.procon.org/ http://www.drugpolicy.org/drug-facts/10-facts-about-marijuana http://www.medicalmj.org/ http://www.cbsnews.com/news/charlottes-web-marijuana-a-hope-for-kids-with-seizures-despite-unproven-medical-benefits/ http://au.ibtimes.com/articles/539079/20140217/hiv-cure-medical-cannabis-weed-explored-help.htm https://www.facebook.com/THeCureForCancers https://www.facebook.com/stonedvet https://www.facebook.com/tellthetruthfederalgovernment https://www.facebook.com/NCC420 https://www.facebook.com/MMJ411DailyDose https://www.facebook.com/FreeTHC https://www.facebook.com/pages/Sanjay-Gupta https://www.facebook.com/safershirts https://www.facebook.com/pages/Medical-Cannabis-Journal https://www.facebook.com/pages/There-is-a-cure-for-Cancer-but-it-is-not-FDA-approved-Phoenix-Tears-work https://www.facebook.com/RealmofCaring https://www.facebook.com/edrosenthal https://www.facebook.com/OrganaLabsUSA https://www.facebook.com/weedsearch https://www.facebook.com/pages/California-Cannabis-Coalition https://www.facebook.com/CannabinoidsCureDisease https://www.facebook.com/pages/Cannabis-For-PTSD https://www.facebook.com/CannaFarmersMarkets https://www.facebook.com/DrugDealersDontID https://www.facebook.com/CNMagazine https://www.facebook.com/PotTV https://www.facebook.com/pages/A-World-Without-Seizure https://www.facebook.com/sensibletacoma https://www.facebook.com/HighTimesMedicalMJ https://www.facebook.com/seattlehempfest https://www.facebook.com/iweedusa https://www.facebook.com/pages/American-Cannabis-Coalition i am looking for interested human's who want to create a store for 95% CBD High Strain's focused on Medical Needs, oils, edibles, and less then 5% focus on THC side of Cannabis... there is tons of stores to get pot to get stoned, there is 0 stores for CBD only!!! we must (lab test all medical CBD cannabis) who want to help me open a CBD rich co-op, focused 95% on CBD medicinal properties of Cannabis Medicine, meaning we will not carry many THC strains, mainly CBD medical strains & oils only... also we will focus on getting this natural medicine out to the people who need it, not for $$$ profit..but because we care.... we need prices to be fair, there is no way i would ever want to see some kids die because they could not afford a medicine.. are you kidding me??? this goes for anyone living...we are suppose to help one another... come on humans, share the love..... a true open source by donation co-op... non profit, LIFE SAVING is all i care about... you can not buy a life with $$$$ in my eye's i been legal in WA & California since 2005, i personally been to well over 500 clubs, not even 1 focused on CBD CURES.... it is really hard to find anything high in CBD... CBD is the non-psychoactive part of Cannabis...Purely Medical Benefits only... the us government has the only patent.. so you know it works CONTACT ME FOR DETAILS.... currently live in CA Jesus Christ is LORD and Savior the Son of God raised from the dead. All Glory to God. Hallelujah.
Просмотров: 4393 itzz420
Donald I. Abrams, MD. is chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco. He has an Integrative Oncology consultation practice at the UCSF Osher Center for Integrative Medicine. He received an A.B. in Molecular Biology from Brown University in 1972 and graduated from the Stanford University School of Medicine in 1977. After completing an Internal Medicine residency at the Kaiser Foundation Hospital in San Francisco, he became a fellow in Hematology/Oncology at the Cancer Research Institute of the University of California, San Francisco in 1980. He was one the original clinician/investigators to recognize and define many early AIDS-related conditions. He has long been interested in clinical trials of complementary and alternative medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal Cannabis. In 1997 he received funding from the National Institute on Drug Abuse to conduct clinical trials of the short-term safety of cannabinoids in HIV infection. Subsequently he was granted funds by the University of California Center for Medicinal Cannabis Research to continue studies of the effectiveness of cannabis in a number of clinical conditions. He completed a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal. He conducted an NIDA-funded trial investigating the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain. He is now conducting an NIH-funded trial investigating vaporized cannabis in patients with Sickle Cell disease. He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website. For further credentials and a summary of the scientific evidence to be presented to the court, please see Fields of Green for ALL’s Expert Witness page.
Просмотров: 2598 Dagga Couple
At the 2017 meeting of the Research Society on Alcoholism, the symposium “Everything You Ever Wanted To Know About Alcohol Treatment But Were Afraid To Ask: A Primer for Non-Clinicians” covered screening and diagnosis of alcohol use disorder, brief interventions, and referral to treatment, as well as the many treatment options and potential pathways through treatment. The symposium included discussions of approved and experimental medications and various behavioral therapies. To view speaker slides, please visit: https://niaaa.nih.gov/video-everything-you-ever-wanted-know-about-aud-treatment
Просмотров: 2142 NIHOD
At the NORD Rare Disease and Orphan Drug Breakthough Summit in Arlington Virginia, we talked with Janet Woodcock, MD, Director of the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) about the increasing role patients have in the development of orphan drugs and how the FDA understands the need for flexibility in assessing clinical trial design.
Просмотров: 185 Rare Disease Report
Dr. Grace Makari-Judson, medical oncologist and Medical Director of the Comprehensive Breast Program at Baystate Medical Center, discusses latest developments in the research on and treatment of breast cancer as we mark Breast Cancer Awareness Month.
Просмотров: 84 wgby
Since the BCRP was established in 1992, the efforts of breast cancer advocates have resulted in over $2.8 billion in appropriations to the BCRP. The BCRP is recognized as a model biomedical research funding program, and meaningful partnerships have been the foundation of the program's successes from the beginning. The integrated efforts of many dedicated scientists, clinicians, and advocates foster unique opportunities in breast cancer research. The BCRP has created and introduced unique mechanisms to support a broad portfolio of research and training awards that have transformed the breast cancer field and led to significant advances. The BCRP enables the scientific community to propose their most innovative, high-impact ideas that address the urgent need to end breast cancer. Marlene McCarthy, Linda Camerota, Diana Chingos, Patricia Haugen, Vernal Branch, Fran Visco, Andrew Thorburn, Nimmi Ramanujam, Dennis Slamon, Robert Scheneider, Maria Wetzel, Greg Hannon, Victoria Seewaldt, Rebekah Drezek, Stephen Johnston, Mina Bissell, Nora Disis, Christopher Faiman, Joy Simha, Yibin Kang, Stuart Martin, Edward Brown, Leisha Emens, Lyndsay Harris, Joe Gray, Erkki Ruoslahti, Geoffrey Rosenfeld, Amy Bonoff, Shiladtiya Sengupta, Ngina Lythcott
Просмотров: 708 CDMRP
Dr. Jed W. Fahey is a nutritional biochemist with broad training and extensive background in plant physiology, human nutrition, phytochemistry and nutritional biochemistry. He is the director of the Cullman Chemoprotection Center at Johns Hopkins. The reason I've asked him to join us today, in particular, however, is because he has been researching isothiocyanates like sulforaphane for over 20 years and is an exceptional expert in this arena. Dr. Fahey and his colleagues have been, in a big way, at the absolute center of what is a staggering amount of research on these very powerful compounds. There is hardly a topic which we can discuss in which he doesn't have an anecdote about a study he was involved in, or, in some cases, tribal knowledge that may not even be published but is nonetheless interesting and an important part of the story that is unique to his particular vantage point. ▶︎ If you have not seen my previous, extremely in-depth video on sulforaphane, a very important isothiocyanate, please do so: https://www.youtube.com/watch?v=zz4YVJ4aRfg -- Find out more about Dr. Fahey and the Cullman Chemoprotection Center: ▶︎ The Cullman Chemoprotection Center Website: http://www.chemoprotectioncenter.org/ ▶︎ The Cullman Chemoprotection Center Facebook: http://www.facebook.com/chemoprotectioncenter/ ▶︎ Dr. Fahey's Website: http://www.jedfahey.com/ ▶︎ Dr. Fahey on Twitter: http://twitter.com/jedosan --- Follow FoundMyFitness elsewhere: ▶︎ iTunes Podcast: http://itunes.apple.com/us/podcast/foundmyfitness/id818198322 ▶︎ Twitter: http://twitter.com/foundmyfitness ▶︎ Facebook: http://www.facebook.com/foundmyfitness ▶︎ Instagram: http://www.instagram.com/foundmyfitness ▶︎ Email newsletter: http://www.foundmyfitness.com/?sendme=lifestyle-heuristic
Просмотров: 81768 FoundMyFitness
'멀티 플레이어' 당뇨약…"치매•암에도 효과" Nearly one in ten senior citizens in Korea suffers from Alzheimer's disease. Although there is no cure for the most common form of dementia, studies show that diabetes drugs can help effectively slow the progression of the disease. Park Se-young has the details. Diabetes is one of the most common diseases among Korean adults. Diabetes patients are more likely to suffer from Alzheimer's disease as they age due to the link between the two diseases and insulin. Like other cells in the body, neurons in the brain use glucose to fuel their activities. But if the lack of insulin hinders the metabolism of glucose in the brain, brain cells are destroyed and so are memories. Experts say diabetes drugs can alleviate such symptoms. "Diabetes drugs help prevent Alzheimer's disease by supplying the brain with enough energy and improving blood flow in the brain." Another study shows that diabetes drugs are effective against colorectal cancer and breast cancer. In addition to regulating blood sugar levels, insulin also promotes cell growth. But having too much insulin in the body causes uncontrolled growth of abnormal cells, a condition better known as cancer. Diabetes drugs can prevent or treat cancer by helping regulate insulin levels. Since the drugs have already been tested and commercialized, further developing them as cancer fighting agents is expected to save the industry both time and money... and could eventually also help save lives. Park Se-young, Arirang News. Visit ‘Arirang News’ Official Pages Facebook(NEWS): http://www.facebook.com/newsarirang Homepage: http://www.arirang.com Facebook: http://www.facebook.com/arirangtv Twitter: http://twitter.com/arirangworld Instagram: http://instagram.com/arirangworld
Просмотров: 111 ARIRANG NEWS
The theme of TEDxPurdueU 2012 was "...innovation." The speakers selected were Purdue students, alumni, and faculty whose stories shed unique light on various aspects of the creative process from idea conception to reality. NOTE: There are some minor graphic images of a surgical procedure. Philip Low has received several national and international research awards, an NIH Merit Award, and both of Purdue University's awards for outstanding research. He has published over 270 refereed articles and currently serves on 4 editorial boards and several external advisory boards for major institutions. Philip's research into receptor-targeted therapeutic and imaging agents has lead to more than 30 U.S. patents/patents pending. Thus far, the development of these patents has yielded 5 targeted drugs that are currently undergoing human clinical trials for kidney, ovarian, breast, lung, brain and endometrial cancers. He has founded a company called Endocyte Inc. based on this technology. Philip has been a member of Purdue University faculty since 1976 and is currently the Ralph C. Corley Distinguished Professor of Chemistry.
Просмотров: 2838 TEDx Talks
January 6, 2012 - The Genomics in Medicine Lecture Series More: http://www.genome.gov/27546022
Просмотров: 4004 National Human Genome Research Institute
2018 Demystifying Medicine: The New Frontier: Immunotherapy of cancer Air date: Tuesday, February 6, 2018, 4:00:00 PM Category: Demystifying Medicine Runtime: 01:46:18 Description: The Demystifying Medicine Lecture Series is designed to help bridge the gap between advances in biology and their applications to major human diseases. The lectures include presentations of patients, pathology, diagnosis, and therapy in the context of major diseases and current research. All clinicians, trainees including fellows, medical students, Ph.D. students, and other healthcare and research professionals are welcome to attend. For more information go to https://demystifyingmedicine.od.nih.gov Author: James Gulley, MD, PhD, NCI, NIH and James Hodges, PhD, MBA, NCI, NIH Permanent link: https://videocast.nih.gov/launch.asp?23701
Просмотров: 681 nihvcast
Roswell Park Cancer Institute recently announced a new clinical trial of a cancer vaccine. Dr. Kelvin Lee, the Jacobs Family Chair of Immunology at Roswell Park Cancer Institute, discusses what the vaccine is all about and what the future holds for additional immunology approaches for a variety of cancers.
Просмотров: 1049 RPCICancerTalk
Associate Professor, Surgery Specialties: Surgery Clinical Interests: Breast cancer and melanoma Michael S. Sabel, MD is an Associate Professor of Surgery in the Division of Surgical Oncology. Dr. Sabel received his Bachelors degree from Pennsylvania State University and a medical degree from Temple University School of Medicine in Philadelphia. Postgraduate training in General Surgery was received at Rush-Presbyterian-St. Luke's Medical Center in Chicago. Dr. Sabel completed an NIH-T32 research fellowship in tumor immunology and a surgical oncology fellowship at Roswell Park Cancer Institute in Buffalo, NY. Dr. Sabel joined the faculty at the University of Michigan in 2001. Dr. Sabel's clinical interests are in the area of surgical oncology, with special expertise in breast cancer and melanoma. Areas of interest include cryoablation of breast cancer and the use of immunotherapy in the treatment of both breast cancer and melanoma. Dr. Sabel is also extensively involved in both clinical and basic science research at the University of Michigan. He is the Director of the University of Michigan Comprehensive Cancer Center Breast Cancer Clinical Outcomes Project and is principal investigator on several clinical trials in breast cancer and melanoma. In addition to his clinical research interests, his basic science research has been focusing on the identification of unique biomarkers in breast cancer and melanoma to help guide surgical and adjuvant therapy and researching the generation of systemic immune responses from local therapies.
Просмотров: 1251 Michigan Medicine
If you missed Dr. Dorigo's lecture on clinical trials for gynecologic cancers, you can watch it here. Part of a quarterly series from the Stanford Women’s Cancer Center featuring talks on women’s cancers, this talk focuses on clinical trials and why they are important for patients. Join us to learn more about clinical trials available at Stanford for gynecologic cancers.
Просмотров: 693 Stanford Health Care
June 7, 2016 - Genomics and Health Disparities Lecture Series More: https://www.genome.gov/27561525
Просмотров: 565 National Human Genome Research Institute
Anas Younes, MD, from the Memorial Sloane-Kettering Cancer Center, New York, NY, talks to us about harmonising the criteria for evaluating response in lymphoma clinical trials with the Response Evaluation Criteria in Solid Tumors (RECIST). A group of international lymphoma experts from academic centers and pharmaceutical companies, radiologists, and statisticians have collaborated to harmonize lymphoma response criteria with RECIST, hypothesizing that single-dimension measurement may be used to assess response with results similar to those with standard criteria, as detailed by Prof. Younes. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
Просмотров: 130 VJHemOnc – Video Journal of Hematological Oncology
Outer Office, 6-10-2013 (Transcript Below) Governor Christie: There probably isn't a family in this state, including my own that hasn't been affected by the physical and emotional pain that comes with these devastating words: you have cancer Each year nearly 48,000 New Jerseyans are diagnosed with the disease with prostate, breast and lung cancers among the most common forms diagnosed here in New Jersey. Approximately 17,000 residents lose their battle with cancer every year. New Jersey is committed to the fight against cancer from our state cancer registry which collects and analyzes cancer statistics, trends and research activities to our New Jersey Cancer Education and Early Detection Program, NJ CEED, which provides life saving screenings, cancer outreach and education and follow up services to the uninsured. I was pleased to be a part of last year's groundbreaking of the 100 million dollar state of the art Cooper Cancer Institute, a facility that will bring advanced diagnostic and treatment technologies to the greater Camden community and South Jersey region. Today I am thrilled to announce a new and exciting partnership that will continue the momentum with the collaboration of MD Anderson, according to U.S. News & World Report, the leading cancer treatment institute in the world and Cooper Cancer Institute to bring world class treatment, care and research to New Jerseyans living with cancer. New Jersey has always been at the forefront of some of the most revolutionary medical innovations, treatments, and discoveries, are pharmaceutical industry has played an enormous role in partnering with our academic institutions and our healthcare institutions in providing this type of care. Through this new innovative alliance Cooper Cancer Institute will be able to expand its leading cancer treatment programs in New Jersey saving lives and providing hope and courage for our cancer patients and their families. And I suspect that this will extend well beyond the borders of Cooper to other places in New Jersey, Pennsylvania and Delaware. I want to welcome MD Anderson to New Jersey. It is an extraordinary moment for our state to have the leading cancer treatment institute in the world come to New Jersey and expand their reach. And I want to applaud the efforts of the people at Cooper to bring this partnership together and to work with everyone in the state to help to defeat cancer in New Jersey.
Просмотров: 523 GovChristie
https://weillcornell.org/gicancer Jonathan Lowenberg sought out stomach cancer clinical trials when he was diagnosed with a tumor in his GI junction. He wanted to choose a cancer treatment center that could not only offer phenomenal treatment options, but a doctor and hospital with a great reputation, and who would be understanding of his unique needs as a patient. When Dr. Manish Shah, Medical Director at the Weill Cornell Medicine Gastrointestinal (GI) Oncology Program, offered Jonathan the option to participate in a clinical trial, he accepted immediately, as Weill Cornell had a long history of successful and groundbreaking research and clinical trials. Within 11 weeks his stage 3 cancer was completely gone. According to Jonathan, the personalized care and treatment he received led to results that were “amazing and quite extraordinary.” He considers Dr. Shah and the GI cancer team at Weill Cornell Medicine to have given him “a second act.” Call us now at 646-962-6200, or click the link below to learn more: https://weillcornell.org/gicancer Stomach Cancer Clinical Trials NYC Stomach Cancer Center NY Stomach Cancer Chemotherapy NYC Stomach Cancer Treatment Stomach Cancer Options Stomach Cancer Research 1305 York Ave., 12th floor New York, NY 10065 Related Videos: https://youtu.be/hhX-bDgLZtU https://youtu.be/oSrDqvs-jck https://youtu.be/eOU9tPcurqs You know it's shock I mean any time you find out something like this, where you literally are told that you have a stage three cancer. I was just in complete shock. My choice, when I did get my bearings together, was to pick someone who had a great reputation. Someone who was going to be understanding of the patient, and who was actually going to look at me as a person. It's like family. I mean this is a institution that when you go through something so serious like cancer, they make you feel like a family here. When the patient comes and sees us, they really feel that they are individually taken care of. Our goal is to give people the best opportunity for the best outcomes with the best promotion of health. So I was on a standard regimen of chemotherapy, but then Doctor Shah asked me if I would participate in the clinical trial that Weill Cornell was sponsoring with NIH, and I didn't even hesitate. The entire cancer was gone after 11 weeks. It's amazing, it's quite extraordinary. Manish Shah and his incredible team at Weill Cornell have given me a second act, and an act that I don't take lightly. Walk through Central Park every day now and look at every tree, and every flower that blooms, and it has a different aura for me. For more info, click this link: https://youtu.be/oSrDqvs-jck https://www.google.com/#tbm=vid&q=Stomach+Cancer+Clinical+Trials+NY Video production, video search engine optimization and video marketing provided by Video SEO Pro, Inc. To learn more give us a call at (914) 368-9600 or click the link below. http://www.myvideoseopro.com/lp001
Просмотров: 422 Weill Cornell Gastrointestinal Oncology Program
TRACO 2018 - Ovarian cancer and immune checkpoints Air date: Monday, September 17, 2018, 4:00:00 PM Category: TRACO Runtime: 01:52:38 Description: Prostate cancer and Immune checkpoints For more information go to http://ccr.cancer.gov/training/trainee-resources/courses-workshops/traco Author: Christina M. Annunziata, M.D., Ph.D., Women's Malignancies Branch, CCR, NCI, NIH and Stephanie L. Goff, M.D., Associate Research Physician, CCR, NCI, NIH Surgery Branch Permanent link: https://videocast.nih.gov/launch.asp?26054
Просмотров: 20 nihvcast
January 28, 2016 - A Quarter Century after the Human Genome Project's Launch: Lessons Beyond the Base Pairs Seminar Series More: http://www.genome.gov/HGP25/
Просмотров: 1465 National Human Genome Research Institute
The Miller-Coulson Academy celebrates the best clinicians at Johns Hopkins Medicine and entrusts them to develop excellence among their peers and students. Using external peer review and other rigorous metrics, the academy is having an impact internally and nationally as it gains momentum and recognition for its pioneering work. For more information, visit http://www.hopkinsmedicine.org/innovative/signature_programs/academy_of_clinical_excellence
Просмотров: 752 Johns Hopkins Medicine
Boris Minev, M.D., Assistant Project Scientist, UCSD Cancer Center discusses new strategies for the development of cancer vaccines in this presentation by Stein Institute for Research on Aging. Series: "SIRA (Sam and Rose Stein Institute for Research on Aging)" [6/2002] [Health and Medicine] [Show ID: 6003]
Просмотров: 1896 University of California Television (UCTV)
Myung S. Park, M.D., a trauma surgeon at Mayo Clinic and Teron Cox, an associate clinical research coordinator, discuss the study they are currently conducting on blood clots, its impact on the community, and who can become involved in the study. Both researchers were promoting and discussing their study with members of the community on Thursday, June 21, at the Center for Translational Science Activities (CTSA) booth located in the Annenberg Plaza in Rochester, Minn.
Просмотров: 320 Mayo Clinic
The retreat gives cancer survivors a chance to relax and refocus and provides opportunities for meeting others who share some of the same concerns associated with living with cancer. Any adult who has been diagnosed with cancer is invited to attend.
Просмотров: 105 Tyler Morning Telegraph
Richard Harris is one of the nation's most-celebrated science journalists, covering science, medicine, and the environment for twenty-nine years for NPR, and the three-time winner of the AAAS Science Journalism Award. He discusses his new book "Rigor Mortis: How Sloppy Science Creates Worthless Cures, Crushes Hope, And Wastes Billions". American taxpayers spend $30 billion annually funding biomedical research. By some estimates, half of the results from these studies can't be replicated elsewhere -- the science is simply wrong. Often, research institutes and academia emphasize publishing results over getting the right answers, incentivizing poor experimental design, improper methods, and sloppy statistics. Bad science doesn't just hold back medical progress, it can sign the equivalent of a death sentence. How are those with breast cancer helped when the cell on which 900 papers are based turns out not to be a breast cancer cell at all? How effective could a new treatment for ALS be when it failed to cure even the mice it was initially tested on? More information about the author and book at: https://goo.gl/FYPYWY Get the book here: https://goo.gl/0Q19E6.
Просмотров: 2861 Talks at Google
2018 Demystifying Medicine: Does inflammation cause cardiovascular disease? If so, how? Air date: Tuesday, February 13, 2018, 4:00:00 PM Category: Demystifying Medicine Runtime: 01:29:28 Description: The Demystifying Medicine Lecture Series is designed to help bridge the gap between advances in biology and their applications to major human diseases. The lectures include presentations of patients, pathology, diagnosis, and therapy in the context of major diseases and current research. All clinicians, trainees including fellows, medical students, Ph.D. students, and other healthcare and research professionals are welcome to attend. For more information go to https://demystifyingmedicine.od.nih.gov/ Author: Alan Remaley, MD, PhD, NHLBI, NIH and Nehal Mehta, MD, NHLBI, NIH Permanent link: https://videocast.nih.gov/launch.asp?23710
Просмотров: 836 nihvcast
IPPCR 2016: Ethical Principles in Clinical Research Air date: Monday, January 04, 2016, 5:00:00 PM Category: IPPCR Runtime: 01:05:25 Description: The Introduction to the Principles and Practice of Clinical Research (IPPCR) is a course to train participants on how to effectively conduct clinical research. The course focuses on the spectrum of clinical research and the research process by highlighting epidemiologic methods, study design, protocol preparation, patient monitoring, quality assurance, and Food and Drug Administration (FDA) issues. For more information go to http://clinicalcenter.nih.gov/training/training/ippcr1.html Author: Christine Grady, R.N., Ph.D., NIH Permanent link: http://videocast.nih.gov/launch.asp?19408
Просмотров: 3226 nihvcast
David B. Dix, MBChB, FRCPC, FAAP and Clinical Professior at the Department of Pediatrics discusses a report from the Children's Oncology Group studies AREN0532 and AREN053 at ASCO 2015. Augmentation of therapy for favorable-histology Wilms' Tumor with combined loss of heterozygosity of chromosomes 1p and 16q at the American Society of Clinical Oncology 2015 Annual Meeting. MDLinx Conference Coverage - 2015 ASCO Annual Meeting: http://www.mdlinx.com/conference-interview/asco-2015/index.cfm MDLinx: http://www.mdlinx.com/ Smartest Doc & Board Exam Prep: http://www.thesmartestdoc.com/ M3 USA: http://usa.m3.com/ Follow MDLinx: Facebook - https://www.facebook.com/MDLinx Twitter - https://twitter.com/MDLinx Google+ - https://plus.google.com/+Mdlinx/
Просмотров: 166 MDLinx
Comprehensive Molecular Profiling to Support Treatment Recommendations for Advanced Cancer Air date: Wednesday, November 13, 2013, 3:00:00 PM Runtime: 01:04:27 Description: NIH Wednesday Afternoon Lecture Series Prior to joining TGen, Dr. Carpten was an intramural tenure track investigator with the Cancer Genetics Branch of the National Human Genome Research Institute (NHGRI), NIH, a group that pioneered a number of innovative technologies and methods to study the underlying genetics of cancer. At NIH, he co-led the first published genome wide scan for prostate cancer susceptibility genes published in 1996 in Science. His lab subsequently discovered germ-line mutations in theRNASEL gene in HPC1-linked hereditary prostate cancer families. His contigs of the 1q24-q31 region of the human genome became the framework and template for sequencing of that 20 megabase region by the Human Genome Project. These data were also used for the subsequent discovery of two other disease genes. The PRG4 gene mapped to 1q24 and mutations within this gene result in CACP, a congenital joint disease. Also mutations in theHRPT2 gene, which maps to 1q31, were discovered in the Carpten lab and lead to hyperparathyroidism jaw-tumor syndrome. HRPT2mutation and parafibromin IHC assays are currently being developed as a clinical diagnostics for parathyroid cancer. Dr. Carpten also has an intense focus on understanding the role of biology in disparate cancer incidence and mortality rates seem among minority populations. Through his leadership, the African American Hereditary Prostate Cancer Study (AAHPC) Network was conceived. This study has become a model for genetic linkage studies in underrepresented populations and led to the first genome wide scan for prostate cancer susceptibility genes in African Americans. More recently, his group has discovered a number of single nucleotide polymorphisms, which confer increased risk of developing prostate cancer. More recently, Dr. Carpten has begun to apply Next Generation Sequencing (NGS) technologies for deep genomic profiling of tumors. These technologies offer the opportunity to sequence entire cancer genomes to discovery of mutations, copy number changes, and rearrangements such as translocations. It is his ultimate hope that his work will lead to more accurate means of cancer diagnosis and to the adoption of knowledge based therapeutic decision-making toward improving outcomes in cancer patients. For more information go to http://wals.od.nih.gov Author: John Carpten, Ph.D., Senior Investigator/Division Director, Division of Integrated Cancer Genomics, and Deputy Director for Basic Research, Translational Genomics Research Institute, Phoenix, AZ. Permanent link: http://videocast.nih.gov/launch.asp?18164
Просмотров: 467 nihvcast
TRACO 2016: Lymphoma and Ovarian cancer Air date: Monday, September 19, 2016, 4:00:00 PM Category: TRACO Runtime: 01:47:21 Description: Lymphoma and Ovarian cancer For more information go to http://ccr.cancer.gov/trainee-resources-courses-workshops-traco Author: Kieron M. Dunleavy, M.D., NIH and Christina M. Annunziata, M.D., Ph.D., NIH Permanent link: https://videocast.nih.gov/launch.asp?19869
Просмотров: 376 nihvcast
Gary Taubes spoke to Googlers in Mountain View on May 2, 2011 about his book Why We Get Fat: And What to Do About It. About the book: An eye-opening, myth-shattering examination of what makes us fat, from acclaimed science writer Gary Taubes. Building upon this critical work in Good Calories, Bad Calories, Taubes revisits the urgent question of what's making us fat and how we can change in this exciting new book. Persuasive, straightforward, and practical, Why We Get Fat makes Taubess crucial argument newly accessible to a wider audience. Taubes reveals the bad nutritional science of the last century, none more damaging or misguided than the calories-in, calories-out model of why we get fat, and the good science that has been ignored, especially regarding insulins regulation of our fat tissue. He also answers the most persistent questions: Why are some people thin and others fat? What roles do exercise and genetics play in our weight? What foods should we eat, and what foods should we avoid? Packed with essential information and concluding with an easy-to-follow diet, Why We Get Fat is an invaluable key in our understanding of an international epidemic and a guide to what each of us can do about it. About the Author: Gary Taubes is a contributing correspondent for Science magazine, and his writing has also appeared in The Atlantic, The New York Times Magazine, and Esquire. His work has been included in The Best of the Best American Science Writing (2010), and has received three Science in Society Journalism Awards from the National Association of Science Writers, the only print journalist so recognized. He is currently a Robert Wood Johnson Foundation Investigator in Health Policy Research at the University of California, Berkeley School of Public Health.
Просмотров: 171991 Talks at Google
Jennifer Obel, MD and Eric Winer, MD review and highlight disease-specific topics and oncology-related subjects as presented at the ASCO Annual Meeting, followed by questions and answers. This session took place on Saturday, June 6, 2010.
Просмотров: 328 Cancer.Net
Turmeric (Curcuma longa), is a popular herb with thousands of years of traditional use in Ayurvedic and Traditional Chinese Medicine, commonly used for reducing inflammation, but should you actually be taking it? Find out here! BioSchwartz Turmeric Curcumin with Bioperine - http://amzn.to/2g6xmiL SynchroGold - http://gold.besynchro.com/ Scientific Literature: Akuri, M. C., Barbalho, S. M., Val, R. M., & Guiguer, E. L. (2017). Reflections about Osteoarthritis and Curcuma longa. Pharmacognosy Reviews, 11(21), 8–12. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414457/ Banik, U., Parasuraman, S., Adhikary, A. K., & Othman, N. H. (2017). Curcumin: The spicy modulator of breast carcinogenesis. Journal of Experimental & Clinical Cancer Research : CR, 36, 98. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517797/pdf/13046_2017_Article_566.pdf Daily, J. W., Yang, M., & Park, S. (2016). Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: A systematic review and meta-analysis of randomized clinical trials. Journal of Medicinal Food, 19(8), 717–729. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003001/pdf/jmf.2016.3705.pdf Ghorbani, Z., Hekmatdoost, A., & Mirmiran, P. (2014). Anti-Hyperglycemic and Insulin Sensitizer Effects of Turmeric and Its Principle Constituent Curcumin. International Journal of Endocrinology and Metabolism, 12(4), e18081. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338652/pdf/ijem-12-04-18081.pdf Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013). Therapeutic roles of curcumin: Lessons learned from clinical trials. The AAPS Journal, 15(1), 195–218. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535097/pdf/12248_2012_Article_9432.pdf Ma, X.-W., & Guo, R.-Y. (2017). Dose-dependent effect of Curcuma longa for the treatment of Parkinson’s disease. Experimental and Therapeutic Medicine, 13(5), 1799–1805. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443238/pdf/etm-13-05-1799.pdf Nagpal, M., & Sood, S. (2013). Role of curcumin in systemic and oral health: An overview. Journal of Natural Science, Biology, and Medicine, 4(1), 3–7. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633300/ Rahimi, H. R., Mohammadpour, A. H., Dastani, M., Jaafari, M. R., Abnous, K., Ghayour Mobarhan, M., & Kazemi Oskuee, R. (2016). The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna Journal of Phytomedicine, 6(5), 567–577. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052420/pdf/AJP-6-567.pdf Verma, V. (2016). Relationship and interactions of curcumin with radiation therapy. World Journal of Clinical Oncology, 7(3), 275–283. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896895/pdf/WJCO-7-275.pdf Wu, A., Noble, E. E., Tyagi, E., Ying, Z., Zhuang, Y., & Gomez-Pinilla, F. (2015). Curcumin boosts DHA in the brain: implications for the prevention of anxiety disorders. Biochimica et Biophysica Acta, 1852(5), 951–961. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754352/pdf/nihms663853.pdf Xu, Y., & Liu, L. (2017). Curcumin alleviates macrophage activation and lung inflammation induced by influenza virus infection through inhibiting the NF‐κB signaling pathway. Influenza and Other Respiratory Viruses, 11(5), 457–463. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596526/pdf/IRV-11-457.pdf Also, be sure to check us out at - Subscribe - http://www.mikethecaveman.com Like - http://www.facebook.com/paleoprimal.longisland Follow - http://www.instagram.com/mikethecaveman Like - http://www.twitter.com/mikethecaveman Become a Patron - http://www.patreon.com/mikethecaveman Get Your Own Official #AskMikeTheCaveman Shirt - https://teespring.com/stores/askmikethecaveman
Просмотров: 49 Mike The Caveman
Sonya Stenfelt PhD at Karolinska Institute talks about Embryonic stem cell-based therapy for advanced macula degeneration Our objective is to develop a safe and efficient cell therapy for advanced dry macular degeneration by transplanting healthy retinal pigment epithelial (RPE) cells differentiated from embryonic stem cells (hESC). We use hESC lines derived and cultured on recombinant human laminin 521 under fully chemically-defined and animal substance-free conditions. Preliminary results show that we can successfully differentiate these lines into RPE-like cells that exhibit the characteristic cobblestone morphology, pigmentation and express RPE-specific markers. Selection of homogenous cell RPE populations at optimal differentiation stage in combination with the relevant laminin isoforms is under exploration followed by functional tests in rats. Read more about BioLamina at www.Biolamina.com Follow us on twitter: https://twitter.com/biolamina and LinkedIn https://www.linkedin.com/company/biolamina-ab
Просмотров: 223 BioLamina
February 11, 2015 Lecture Title: The Complexity of Genetic Susceptibility to Cancer More: http://www.genome.gov/27559854
Просмотров: 1967 National Human Genome Research Institute
This is my life and it's my right to live The way I want to live each day That's what I wanna say And this is my song Aretha Franklin Beginning in 2009, HUD landlord began interfering in my ability to receive medical treatment because I "have too many appointments" HUD and the State of Connecticut advised me that in order for me to receive scans monitoring the lumps in my left breast and other masses, I would have to give landlord a list of my appointments "for landlord to okay or not". In the fall of 2010, I had a blockage removed from my colon and a physical examination of the lumps in my breast, without getting permission - although I did give landlord several weeks' notice, in hopes that landlord would not let men into my apartment while I was under the influence of anesthesia - (as they had done just a month before, while I was in the shower). In retaliation, landlord informed HUD and the State I was going to these appointments in order to interfere with repairs being made in my apartment, although no repairs were scheduled and landlord had written notice of the dates of my appointments well in advance. HUD and the State of Connecticut decided that since I was making and keeping tumor related appointments without landlord's approval, that from now I, I can only go to medical appointments during April - October, although some of my scans need to occur every three months - like to the mass on my thyroid. The State investigator even advised landlord how to take action against me the next time I go. New Samaritan Corporation continues efforts to interfere with my medical treatment: https://www.facebook.com/media/set/?set=a.197167627100311.1073741826.100004212254046&type=1&l=52ced47ed5 https://www.facebook.com/media/set/?set=a.238279359620543.48429.100003154439023&type=3&l=f4d9f12a39 http://newsam.org/board.html http://newsam.org/properties.html Each winter since 2009, landlord has used threats against my car to limit my ability to receive medical treatment and care during the six months of winter "because you have too many appointments." No other tenant is required to stay home all winter to move their cars if plow comes. All other tenants are allowed to park in vacant spaces, taking up to three parking spaces in their lot AND are not ever required to move their cars when plow comes. Some tenants cars have not been moved for over a year. Landlord says I don't have the same rights as other tenants. HUD and the State of Connectiuct agree. Landlord does not say I cannot take medical transportation - landlord does not provide me with a clear path AND states my car will be damaged or towed if I get a ride to have tumors are scanned. The last time I spoke with Mr. Jeffrey Sussman of HUD, he stated, "It shouldn't be snowing for too much longer." The Final Report of the Connecticut Commission on Human Rights states I need to schedule my appointments according to the weather. The State of Connecticut and HUD say I don't have a right to early detection testing because I am disabled and not able to walk over unshoveled sidewalks or drive myself for scans. HUD's Jeffrey Sussman holds seminars training landlords on the disabilities they don't have to accommodate - like being hearing-impaired, having limited mobility and not being able to drive: Unreasonable Accommodations Seminar - held by HUD "fair" housing: http://conn-nahro.org/Resources.ashx?id=b66641f5-6379-401c-af7a-92ce90c5b23c The State of Connecticut called the removal of medium size polyp blocking my colon "a medical excuse" and advised HUD landlord how to take action against me for having it done. Documentation: https://www.facebook.com/media/set/?set=a.301235579986143.66567.100002991104349&type=1&l=6c5d81b33c https://www.facebook.com/media/set/?set=a.238279359620543.48429.100003154439023&type=1&l=f4d9f12a39 https://www.facebook.com/media/set/?set=a.152964898158789.29237.100003358385788&type=1&l=f2d3c81535 https://www.facebook.com/media/set/?set=a.106645346152540.16956.100004212254046&type=1&l=f8f53afbba https://www.facebook.com/media/set/?set=a.137098873078725.23883.100003358385788&type=1&l=0675f15486 https://www.facebook.com/media/set/?set=a.337205369729897.79717.100003213090084&type=1&l=cce6ecaa94 http://www.nidcd.nih.gov/health/balance/pages/meniere.aspx UPDATE: April 12th, 2013 According to RAP, this is the third year in a row landlord has withheld document RAP needs to continue my rental assistance. Fortunately, I have a copy of the document I signed and gave to landlord - with property manager's signature, which she did not date, possibly to make it seem like I was the one holding up the paperwork, like landlord told HUD last year. It is so sad how HUD continues to support landlord's efforts to cause me harm and endanger my life. http://youtu.be/DmciNL5iV9s I created this video with the YouTube Slideshow Creator (http://www.youtube.com/upload)
Просмотров: 441 NewSamaritanSlumLife
John Megjugorac, Esq.speaks on Employment Department Obtains $525,000.00 Verdict on Behalf of Ginarte Client. To read click here: http://www.ginarte.com/2014/06/employment-department-obtains-525000-00-verdict-behalf-ginarte-client/ With over 150 years of combined experience, the attorneys at Ginarte Gallardo González Winograd LLP have been serving clients in Newark, New York City, Perth Amboy, Union City, Elizabeth, Clifton, Queens and throughout the New York, New Jersey metro area. Our team of 150 legal professionals concentrates on a variety of legal matters including personal injury, worker's compensation, employment law, social security and construction accidents. For more information you can find us at http://www.ginarte.com Call 1-888-GINARTE (1-888-446-2783) now for a free consultation or fill out our online form. You can also visit one of our 7 convenient locations: Newark: 400 Market Street, Newark, NJ 07105 Union City: 4430 Bergenline Avenue, Union City, NJ 07087 Elizabeth: 948 Elizabeth Avenue, Elizabeth, NJ 07201 Clifton: 1137 Main Avenue, Clifton, NJ 07011 Perth Amboy: 352 New Brunswick Avenue, Perth Amboy, NJ 08861 New York: 225 Broadway 13th Floor, New York, NY 10007 Queens: 82-16 Roosevelt Avenue, Jackson Heights, NY 11372
Просмотров: 77 Joseph Ginarte
→Subscribe for new videos every day! https://www.youtube.com/user/TodayIFoundOut?sub_confirmation=1 →How "Dick" came to be short for 'Richard': https://youtu.be/BH1NAwwKtcg?list=PLR0XuDegDqP2Acy6g9Ta7hzC0Rr3RDS6q Never run out of things to say at the water cooler with TodayIFoundOut! Brand new videos 7 days a week! More from TodayIFoundOut Keanu Reeves Gives Away Millions ... and 6 other Celebrity Facts https://youtu.be/6F_NzmAQbg4?list=PLR0XuDegDqP1IHZBUZvKkPwkTr6Gr0OBO When Humans Started Shaving Different Parts of Our Bodies https://youtu.be/Am7uIOSxSH4?list=PLR0XuDegDqP0GESJ0DgpgTcThLJVEbFs8 In this video: The human body really is an engineering marvel; even the most substandard model comes outfitted with the latest in 576 megapixel camera technology, a self contained bio-energy factory, self-healing triplicate outer protection that can handle quite a bit of rough-and tumble, and an amazing amount of memory and processing power. Want the text version?: http://www.todayifoundout.com/index.php/2015/11/why-do-men-have-nipples/ Sources: http://www.livescience.com/45732-can-men-lactate.html http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706056/ http://www.livescience.com/32467-why-do-men-have-nipples.html http://gizmodo.com/what-is-the-resolution-of-the-human-eye-1541242269 http://www.scientificamerican.com/article/why-do-men-have-nipples/ https://en.wikipedia.org/wiki/Nipple http://health.howstuffworks.com/human-body/parts/why-men-have-nipples.htm https://en.wikipedia.org/wiki/Vestigiality http://www.bbc.com/future/story/20150512-the-truth-about-extra-nipples http://kellymom.com/bf/got-milk/extra-breast-tissue/ https://en.wikipedia.org/wiki/Milk_line http://breastcancer.about.com/od/nippleandareolahealth/g/milk-lines-definition.htm
Просмотров: 27332 Today I Found Out
In his first town hall meeting, NCI Director, Dr. Norman Sharpless, highlights a few broad areas where he believes NCI has a role to play in advancing progress against cancer. https://www.cancer.gov/about-nci/leadership/director/presentations
Просмотров: 833 National Cancer Institute
Christopher P. Austin, M.D. Director, NIH Chemical Genomics Center National Institutes of Health Presented at Chordoma Community Conference, June 27, 2009 Dr. Austin speaks of using robot technology to test thousands of drugs on cancer cells, effectively shortening the time needed to find possible treatments.
Просмотров: 1036 Chordoma Foundation
JOIN OUR COMMUNITY ON FACEBOOK (www.facebook.com/uoa.health) Stay updated on upcoming HEALTH MATTERS and conversations about health and medical research. ABOUT THIS SESSION: Humans inherit three billion DNA data points from both their mother and their father–a total of 6 billion data points–in every cell in their body. From conception, every data point is replicated, at every cell division, as you grow and age. What many of us don’t know is that mistakes or “mutations” can happen at every stage and steadily accumulate as we age. Environmental factors, such as the sun or tobacco smoke to name a few, can cause mutations. But what are the consequences of these mutations? While we only know what 2% of these DNA data points do, we know that altering just one data point can cause catastrophic disease that can present in utero, at birth or later in life. Genomics looks at as many DNA data points as possible to give diagnoses and guides treatment from before birth to death, looking at mutations you are born with, and mutations you acquire. Professor Scott will look at what DNA analyses are done as part of standard care for genetic diseases and cancer, and what can be done as exemplified by research using new and cheaper technologies for DNA sequencing. ABOUT THE SPEAKER: Professor Hamish Scott heads the Department of Genetics and Molecular Pathology at the Centre for Cancer Biology, an alliance between SA Pathology and the University of South Australia. Professor Scott completed his PhD and first post-doc at the Adelaide Women’s and Children’s Hospital, followed by five years at the University of Geneva Medical School, Switzerland. He has led many international collaborations to identify genes causing human genetic diseases, from severe birth defects to familial cancer predisposition syndromes. He has been central to introducing new genetic testing technologies to SA to personalise patient treatments. www.centreforcancerbiology.org.au/members/hamish-s-scott/
Просмотров: 173 Health & Medical Sciences - University of Adelaide